ATAI Life Sciences Overview
- Founded
-
2018
- Status
-
Public
- Employees
-
87
- Stock Symbol
-
ATAI
- Investments
-
16
- Share Price
-
$1.88
- (As of Tuesday Closing)
ATAI Life Sciences General Information
Description
ATAI Life Sciences NV is a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders. Its product candidates include COMP360/Psilocybin therapy, PCN-101/R-ketamine, RL-007/Compound, DMX-1002/Ibogaine, GRX-917/Deuterated etifoxine, VLS-01/DMT, EMP-01/MDMA derivative, RLS-01/Salvinorin A, KUR-101/Deuterated Mitragynine, and DMX-1001/Noribogaine. The business operates geographically in two regions being the United States and Germany.
Contact Information
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Stock Exchange
NAS
Primary Office
- C/o Mindspace
- Krausenstraße 9-10
- 10117 Berlin
- Germany
+49 089 00000000
ATAI Life Sciences Timeline
ATAI Life Sciences Stock Performance
(As of Tuesday Closing)
| Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
|---|---|---|---|---|---|---|
| $1.88 | $1.93 | $1.45 - $6.32 | $320M | 166M | 1.52M | -$1.31 |
ATAI Life Sciences Financials Summary
|
In Thousands, USD |
TTM 30-Sep-2022 | FY 2021 31-Dec-2021 | FY 2020 31-Dec-2020 | FY 2019 31-Dec-2019 |
|---|---|---|---|---|
| EV | 245,627 | 803,177 | ||
| Revenue | 425 | 20,376 | 0 | 0 |
| EBITDA | (144,782) | (136,759) | (101,860) | (17,491) |
| Net Income | (196,251) | (167,808) | (169,843) | (14,138) |
| Total Assets | 342,597 | 414,166 | 111,548 | 62,116 |
| Total Debt | 15,001 | 743 | 2,177 | 157 |
Public Fundamental Data provided by Morningstar, Inc.
disclaimer
ATAI Life Sciences Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
ATAI Life Sciences Comparisons
Description
Primary
Industry
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Financing
Details
ATAI Life Sciences NV is a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health d
Drug Discovery
Berlin, Germany
87
As of 2021
00000
0.000
0000-00-00
00000000
00000
000000
irure dolor in reprehenderit in voluptate velit esse cillum dolore eu fugiat nu
0000 000000000
Boston, MA
000
As of 0000
00000
0.000
0000-00-00
00000000
00000
0000 0
u fugiat nulla pariatur. Excepteur sint occaecat cupidatat non proident, sunt in
0000 000000000
Cambridge, MA
000
As of 0000
00.000
000000000
00.000
Add Comparison
ATAI Life Sciences Competitors (3)
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Karuna Therapeutics | Formerly VC-backed | Boston, MA | 000 | 00000 | 00000000 | 00000 |
| 0000 000000000000 | Formerly VC-backed | Cambridge, MA | 000 | 00.000 | 000000000 | 00.000 |
| 000000 00000000000 | Corporation | New York, NY | 000 | 000.00 | 00000000 | 000.00 |
ATAI Life Sciences Patents
ATAI Life Sciences Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| US-20230024991-A1 | Prodrugs of acyl carnitines | Pending | 23-Jun-2021 | 0000000000 | |
| US-20220388956-A1 | New n,n-dimethyltryptamine salts and crystalline salt forms | Pending | 25-May-2021 | 0000000000 | |
| US-20220339139-A1 | Novel n,n-dimethyltryptamine compositions and methods | Pending | 26-Apr-2021 | 00000000000 | 0 |
| FR-1486515-A | Sealed contact valve for fluid passage | Inactive | 27-May-1966 | F16K31/365 |
ATAI Life Sciences Executive Team (14)
ATAI Life Sciences Board Members (8)
| Name | Representing | Role | Since |
|---|---|---|---|
| Andrea Smiley | ATAI Life Sciences | Board Member | 000 0000 |
| Christian Angermayer | Self | Chairman & Founder | 000 0000 |
| Gregory Weaver | Self | Chief Financial Officer & Board Member | 000 0000 |
| Jason Camm | Self | Board Member | 000 0000 |
| Michael Auerbach | Self | Board Member | 000 0000 |
ATAI Life Sciences Signals
Growth Rate
0.80%
Weekly
Growth
Growth
Weekly Growth
0.80%, 93rd %
-35.5%.
530%
Size Multiple
219x
Median
Size Multiple
219x, 100th %ile
0.00x
0.95x.
413Kx
Key Data Points
Twitter Followers
5.5k
Similarweb Unique Visitors
15.0K
Majestic Referring Domains
314
ATAI Life Sciences Investors
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
|---|
ATAI Life Sciences Investments & Acquisitions (16)
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| 00000000000 | 09-Dec-2021 | 00000 0000 | Drug Discovery | 0000000 0 | |
| 000000000 000 | 14-May-2021 | 0000 | 0000 | Drug Delivery | 0000000 0 |
| 000000 | 07-Apr-2021 | 0000000000 | Therapeutic Devices | 000000000 | |
| 000000000 000 | 06-Nov-2020 | 0000000000 | Drug Discovery | 00000000 | |
| Kures | 09-Jul-2020 | Merger/Acquisition | Drug Discovery | 0000000 0 |
ATAI Life Sciences Subsidiaries (3)
| Company Name | Industry | Location | Founded |
|---|---|---|---|
| Recognify Life Sciences | Drug Discovery | Berlin, Germany | 2018 |
| 00000 | Drug Discovery | Dobbs Ferry, NY | 0000 |
| 000000 | Therapeutic Devices | New York, NY |
ATAI Life Sciences ESG
Risk Overview
Risk Rating
Updated November, 23, 2022
32.83 | High Risk
Risk Scale
A lower score indicates better sustainability
Negl
0-10
Low
10-20
Med
20-30
High
30-40
Severe
40+
Exposure
Exposure refers to the extent to which a company is exposed to different material ESG issues
00.00
Management
Management is related to actions taken to manage ESG issues
00.00
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
00 of 15,638
Rank
00.00
Percentile
Pharmaceuticals
Industry
00 of 1,008
Rank
00.00
Percentile
Pharmaceuticals
Subindustry
00 of 473
Rank
00.00
Percentile
ATAI Life Sciences Exits (3)
| Company Name | Exit Date | Exit Type | Exit Size | Status | Buyers |
|---|---|---|---|---|---|
| 0000000 00000000 | 17-Apr-2020 | 00000 00000 00 | 000.00 | Completed |
|
| 0000000 00000000 | 20-Sep-2018 | 00000 00000 00 | 000.00 | Completed |
|
| COMPASS Pathways | Later Stage VC | 000.00 | Completed |